The global organs-on-chips market, valued at USD 100 million in 2025, is projected to reach USD 129 million in 2026 and USD 944 million by 2035, representing a CAGR of 24.8% during the forecast period 2026-2035. In terms of geographical regions, North America currently holds the highest share, accounting for ~45% of the overall market. In May 2026, Critical Path Institute launched the NAMs Developer Coalition, bringing together developers such as CN Bio, Curi Bio, Emulate, and InSphero to advanc...

The global exoskeleton market, valued at USD 2.9 billion in 2025, is projected to reach USD 3.7 billion in 2026 and USD 20.3 billion by 2035, representing a CAGR of 20.8% during the forecast period 2026 to 2035. The exoskeleton market is gaining relevance as mobility impairment becomes a larger clinical, social, and economic burden. Neurological conditions are now among the leading causes of disability worldwide; in 2025, the World Health Organization reported that neurological conditions affect...

The global cultured meat market, valued at USD 0.27 billion in 2025, is projected to reach USD 0.34 billion in 2026 and USD 229 billion by 2050, representing a CAGR of 31% during the forecast period from 2026 to 2050. In recent years, there has been a perpetual rise in the global population. According to recent estimates provided by the United Nations, the world population is projected to reach 9.8 billion by 2050. This demographic trend is accompanied by an increase in demand for food, particu...

The North America medical device contract manufacturing market, valued at USD 40.9 billion in 2025, is projected to reach USD 43.9 billion in 2026 and USD 75.5 billion by 2035, with a CAGR of 6.2% during the forecast period 2026 to 2035. North America represents the largest and most advanced market for medical device contract manufacturing, driven by its robust medtech ecosystem and strong culture of innovation. The US, in particular, continues to generate significant demand for contract manufac...

The Europe liquid biopsy market, valued at USD 2.0 billion in 2025, is projected to reach USD 2.3 billion in 2026 and USD 7.4 billion by 2035, representing a CAGR of 13.8% during the forecast period 2026 to 2035. Cancer diagnosis has traditionally relied on tissue biopsy, as it provides direct access to tumor material and helps clinicians understand the biological and molecular characteristics of the disease. However, the procedure is often associated with several practical and patient-related l...

The North America cancer metabolism based therapeutics market, valued at USD 1.32 billion in 2025, is projected to reach USD 1.78 billion in 2026 and USD 12.03 billion by 2035, with a CAGR of 23.7% during the forecast period 2026 to 2035. North America continues to report a substantial oncology disease burden, creating sustained demand for therapies that can address difficult-to-treat and genetically defined cancers. In the US alone, around 2.11 million new cancer cases and 626,140 cancer deaths...

The global operating room integration market, valued at USD 2.55 billion in 2025, is projected to reach USD 2.83 billion in 2026 and USD 7.19 billion by 2035, representing a CAGR of 10.92% during the forecast period 2026 to 2035. Alongside this expansion in functionality, the underlying technologies of operating room integration systems are also changing, with newer platforms relying increasingly on software-defined control, IP-based connectivity and networked data exchange to coordinate devices...

The global rapid sterility testing for cell and gene therapies market, valued at USD 0.15 billion in 2025, is projected to reach USD 0.18 billion in 2026 and USD 0.80 billion by 2035, representing a CAGR of 18.0% during the forecast period from 2026 to 2035. The expanding clinical pipeline of advanced therapies has increased the demand for quality control methods that can deliver ultra-fast results. There is a prominent industry shift toward molecular diagnostics that utilize genetic targeting t...

The North America liquid biopsy market, valued at USD 4.5 billion in 2025, is projected to reach USD 5.2 billion in 2026 and USD 17.4 billion by 2035, representing a CAGR of 14.4% during the forecast period 2026 to 2035. Tissue biopsy has historically served as the standard approach for cancer diagnosis and molecular profiling, as it allows clinicians to directly examine tumor tissue and identify disease-specific characteristics. However, its invasive nature often creates challenges for patients...

The global RNAi therapeutics and technology market, valued at USD 6.2 billion in 2025, is projected to reach USD 7.4 billion in 2026 and USD 21.6 billion by 2035, representing a CAGR of 12.6% during the forecast period 2026 to 2035. In June 2026, Arrowhead Pharmaceuticals received European Commission marketing authorization for REDEMPLO® (plozasiran), a small interfering RNA medicine for adults with familial chylomicronemia syndrome. In June 2026, AviadoBio expanded its exclusive license for th...

The global ulcerative colitis market size, valued at USD 13.0 billion in 2025, is projected to reach USD 14.0 billion in 2026 and USD 25.7 billion by 2035, representing a CAGR of 7.0% during the forecast period 2026 to 2035. Based on route of administration, the subcutaneous route dominates (more than 40%) the current market; this trend is unlikely to change in the future. With respect to distribution channels, hospital pharmacies are expected to capture most of the future ulcerative colitis mar...

The global Crohn’s disease market size, valued at USD 9.6 billion in 2025, is projected to reach USD 10.3 billion in 2026 and USD 18.1 billion by 2035, representing a CAGR of 6.5% during the forecast period 2026 to 2035. Based on the route of administration, the subcutaneous route dominates (more than 40%) the future market (2035). The rising prevalence of Crohn’s disease represents a major market opportunity within this domain. Notably, in 2023, an estimated 1 million patients were living w...

The North America pharma cloud services market, valued at USD 5.7 billion in 2025, is projected to reach USD 6.8 billion in 2026 and USD 21.2 billion by 2035, representing a CAGR of 13.5% during the forecast period from 2026 to 2035. Pharmaceutical companies in North America are increasingly adopting AI-enabled cloud platforms to accelerate drug discovery, clinical development, regulatory documentation, manufacturing, and commercial operations. As pharma companies handle large volumes of genomic...

The global PERK inhibitors market is envisaged to rise from USD 46.0 million in 2026 and is projected to reach USD 450.0 million by 2040, growing at a CAGR of 17.7% over the forecast period 2026 to 2040, driven by Phase 1b oncology combination development and research-enablement demand. Based on product / offering type, therapeutic drug candidates is both the dominant and fastest-growing category, holding 34.0% share in 2026 and expanding at 21.3% CAGR through 2040, driven by oncology pipeline v...

The global Duchenne muscular dystrophy market reached USD 5.2 billion in 2026 and is projected to reach USD 28.7 billion by 2040, growing at a CAGR of 13.0% over the forecast period 2026 to 2040, driven by mutation-targeted therapies, gene transfer adoption, and broader rare-disease reimbursement. Based on therapy class, gene therapies capture 34.0% market share in 2026, whereas cell therapies register a 28.4% CAGR through 2040, driven by late-stage cardiac and skeletal-muscle programs. Based on...

The global healthcare interoperability solutions market is expected to rise from USD 5.8 billion in 2026 to reach USD 31.5 billion by 2040, growing at a CAGR of 12.8% over the forecast period 2026 to 2040, driven by regulatory interoperability mandates and cloud-native FHIR adoption. Long-term growth will accelerate as cloud deployment, semantic interoperability, and FHIR APIs reshape procurement through 2040. Oracle Health received TEFCA QHIN designation in November 2025 and linked customer onb...

The global AI-powered pharmacovigilance market is expected to rise from USD 0.83 billion in 2026 and is projected to reach USD 5.59 billion by 2040, growing at a CAGR of 14.6% over the forecast period 2026 to 2040, driven by rising safety-data complexity. Based on deployment model, cloud-based solutions are both dominant and fastest-growing, holding 58.0% share in 2026 and expanding at 16.1% CAGR through 2040, driven by scalable global safety operations.

The global RNAi therapeutics market, valued at USD 2.9 billion in 2025, is projected to reach USD 3.6 billion in 2026 and USD 9.1 billion by 2035, representing a CAGR of 10.8% during the forecast period 2026 to 2035. With respect to route of administration, intravenous administration accounts for the highest share, capturing 45% of the current market. In June 2026, Alnylam Pharmaceuticals and Inceptive Nucleics announced a strategic AI-driven collaboration valued at up to USD 2 billion, includin...

The global large volume wearable injectors market, valued at USD 12.6 billion in 2025, is projected to reach USD 16.4 billion in 2026 and USD 31.4 billion by 2035, representing a CAGR of 7.5% during the forecast period 2026 to 2035. The market numbers have been calculated by taking into account the revenues generated through sales of large volume wearable injectors and related drug-device combination products. Based on market share distribution by therapeutic area, devices used to treat autoimmu...

The global bacteriophage therapy market, valued at USD 58.1 million in 2025, is projected to reach USD 66.5 million in 2026 and USD 266.8 million by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035. In terms of target indication, urinary tract infections hold the highest (around 30%) share of the current market. With respect to route of administration, oral route dominates the current market.